``Guidance for Industry: Assessing Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection;'' Availability; Correction, 40720 [05-13830]
Download as PDF
<![CDATA[
40720
Federal Register / Vol. 70, No. 134 / Thursday, July 14, 2005 / Notices
with review of the application being the
primary goal. The process will include
appropriate coordination between
agency review and inspection staff.
Based on experience gained during the
pilot program and internal knowledge of
manufacturing science, FDA will
develop procedures and guidance for
implementing the new quality
assessment system.
A. Scope
This program will be limited to 12
original NDAs to be submitted by
December 31, 2006, in the CTD format,
paper or electronic. If an applicant
believes that a particular CMC
supplement would be a good candidate
for this pilot program, the applicant is
encouraged to first contact ONDC to
discuss its acceptability. Acceptance
into this program will depend on the
soundness of the drug development
plan and the potential of the proposed
application to affect the development of
the new quality assessment system.
Every effort will be made to ensure that
all pharmaceutical companies have the
opportunity to participate and that
many different drug product types are
included in this pilot program.
This pilot program only affects the
CMC section of the NDA. Existing
regulations and requirements for the
submission of an NDA will not be
waived, suspended, or modified for
purposes of this pilot program.
Participants must submit the NDA,
paper or electronic, in accordance with
21 CFR part 314 and other relevant
regulations.
B. Process
Interested parties should submit to
the Division of Dockets Management
(see ADDRESSES) a written request to
participate in the pilot program
(identified with the docket number
found in brackets in the heading of this
document). The request should include
the following items: (1) The contact
person’s name, company name,
company address, and telephone
number; (2) the name of the drug
product and a brief description (e.g.,
dosage form, indication); (3) a summary
of the drug development plan; (4) a
statement of the potential of the
proposed application to affect the
development of the new quality
assessment system; and (5) a timeline
for end-of-phase-2 and pre-NDA
meetings and NDA submission. All
pharmaceutical companies requesting
participation in the pilot program will
be notified of their acceptance in
writing by ONDC within 60 days of
receipt of the request.
VerDate jul<14>2003
18:32 Jul 13, 2005
Jkt 205001
Potential participants are encouraged
to discuss their plans to participate in
this pilot program with ONDC (e.g., as
part of an end-of-phase-2 or pre-NDA
meeting). Meeting requests for
participating applicants should be
submitted in accordance with the CDER
guidance for industry on ‘‘Formal
Meetings With Sponsors and Applicants
for PDUFA Products’’ (https://
www.fda.gov/cder/guidance/
2125fnl.htm). Once agreement is
reached on participation in this
program, the applicant can meet with
ONDC as frequently as needed before
the submission and during the review
process by submitting requests directly
to ONDC.
The quality assessment under this
pilot program will be conducted under
the direct oversight of the ONDC Office
Director by a team of experienced
scientists who have a good
understanding of the new quality
assessment system and a strong
scientific background in pharmaceutical
development and manufacturing.
A pharmaceutical company may
withdraw from participation in the pilot
program at any time before the NDA is
submitted by notifying ONDC in writing
that it wishes to withdraw from the
program.
III. Comments
Interested persons may submit written
comments on this pilot program to the
Division of Dockets Management (see
ADDRESSES). Two copies of any
comments are to be submitted, except
that individuals may submit one copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. FDA will
consider these comments when
developing a guidance on the new
pharmaceutical quality assessment
system. Received comments may be
seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday. While detailed
information on participating NDAs will
not be publicly available, names of
participating applicants will be made
public.
Dated: July 7, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–13829 Filed 7–13–05; 8:45 am]
BILLING CODE 4160–01–S
PO 00000
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005D–0133]
‘‘Guidance for Industry: Assessing
Donor Suitability and Blood and Blood
Product Safety in Cases of Known or
Suspected West Nile Virus Infection;’’
Availability; Correction
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
The Food and Drug Administration
(FDA) is correcting a notice that
appeared in the Federal Register of June
30, 2005 (70 FR 37863). The document
announced the availability of a guidance
document entitled ‘‘Guidance for
Industry: Assessing Donor Suitability
and Blood and Blood Product Safety in
Cases of Known or Suspected West Nile
Virus Infection.’’ The document
published with inadvertent errors. This
document corrects those errors.
FOR FURTHER INFORMATION CONTACT:
Joyce Strong, Office of Policy and
Planning (HF–27), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–7010.
SUPPLEMENTARY INFORMATION: In FR Doc.
05–12960, appearing on page 37863 in
the Federal Register of Thursday, June
30, 2005, the following correction is
made:
1. On page 37864, in the second
column, under the section heading ‘‘II.
Paperwork Reduction Act of 1995’’, the
second sentence is corrected to read:
‘‘The collection of information in this
guidance for 21 CFR 601.12 was
approved under OMB control number
0910–0338; § 606.170(b) (21 CFR
606.170(b)) has been approved under
OMB control number 0910–0116; and
§ 606.171 has been approved under
OMB control number 0910–0458.’’
Dated: July 8, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–13830 Filed 7–13–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–4971–N–35]
Notice of Submission of Proposed
Information Collection to OMB;
Voucher Homeownership Program
Implementation Survey
Office of the Chief Information
Officer, HUD.
AGENCY:
Frm 00036
Fmt 4703
Sfmt 4703
E:\FR\FM\14JYN1.SGM
14JYN1
]]>Agencies
[Federal Register Volume 70, Number 134 (Thursday, July 14, 2005)]
[Notices]
[Page 40720]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-13830]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005D-0133]
``Guidance for Industry: Assessing Donor Suitability and Blood
and Blood Product Safety in Cases of Known or Suspected West Nile Virus
Infection;'' Availability; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is correcting a notice that
appeared in the Federal Register of June 30, 2005 (70 FR 37863). The
document announced the availability of a guidance document entitled
``Guidance for Industry: Assessing Donor Suitability and Blood and
Blood Product Safety in Cases of Known or Suspected West Nile Virus
Infection.'' The document published with inadvertent errors. This
document corrects those errors.
FOR FURTHER INFORMATION CONTACT: Joyce Strong, Office of Policy and
Planning (HF-27), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-7010.
SUPPLEMENTARY INFORMATION: In FR Doc. 05-12960, appearing on page 37863
in the Federal Register of Thursday, June 30, 2005, the following
correction is made:
1. On page 37864, in the second column, under the section heading
``II. Paperwork Reduction Act of 1995'', the second sentence is
corrected to read: ``The collection of information in this guidance for
21 CFR 601.12 was approved under OMB control number 0910-0338; Sec.
606.170(b) (21 CFR 606.170(b)) has been approved under OMB control
number 0910-0116; and Sec. 606.171 has been approved under OMB control
number 0910-0458.''
Dated: July 8, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-13830 Filed 7-13-05; 8:45 am]
BILLING CODE 4160-01-S
